# Vitamin A and E solution

### **Newborn use only**

Alaut	There are individual forms device for vitagein A and F
Alert	There are individual formularies for vitamin A and E.  The dose recommendation of vitamins A and E eval solution in this formulary is based on the vitamin A.
	The dose recommendation of vitamins A and E oral solution in this formulary is based on the vitamin A content and may not match with vitamin E recommended dosage.
	Vitamin A is expressed as microgram retinol activity equivalents (RAE) or international units (IU) or units.
	1 microgram RAE = 1 microgram retinol = 3.3 units of retinol. (1)
	Vitamin E 1 International Unit (hereafter referred to as "units") = 0.67 mg d-alpha-tocopherol.
	The consensus Australasian lipid formulation provides:
	- 920 units/kg/day of vitamin A at 3 g/kg/day
	- 2.8 IU/kg/day of vitamin E at 150 mL/kg/day.
	Penta-Vite Infant, a commonly used multi-vitamin supplement in Australia, contains vitamin A but doesn't
	contain vitamin E.
Indication	Cholestatic liver disease
Action	Vitamin A: Fat soluble vitamin required for vision, growth and bone development, immune function and
	maintenance of epithelial cells particularly in the retina and respiratory tract tissues.
	Vitamin E: Antioxidant protecting cell membranes from oxidative stress. Active isomer is α-tocopherol.
Drug type	Fat soluble vitamins.
Trade name	Bio-Logical Vitamins A & E oral solution
Presentation	Bio-Logical Vitamins A & E oral solution (50 mL bottle): Each 1 mL contains Retinol palmitate 1.2 mg =
	Vitamin A 2210 units=663 microgram retinol equivalents and d-alpha-tocopheryl acetate 75 mg/mL (102
	units/mL).
Dose	Cholestatic liver disease
	Bio-Logical Vitamins A & E Solution: 1.5 – 2 mL/day in 1 or 2 divided doses.*#
	*Prescription is based on vitamin A component, which would provide a dose between 3315-4420
	units/day. (2) (ANMF consensus)
	#The prescribed dose provides 153 to 204 units/day of vitamin E. Although this vitamin E intake is
	considered excessive, these doses have been used in neonates without any reported toxicity. (3)
Dose adjustment	Therapeutic hypothermia – No information.
	ECMO – Not applicable.
	Renal impairment - No information.  Hepatic impairment – No information.
Maximum dose	nepatic impairment – No imormation.
Total cumulative	
dose	
Route	Oral
Preparation	No preparation is required.
Administration	Oral: Administer undiluted with a feed.
Monitoring	Oral. Administer diffulded with a feed.
Contraindications	Hypersensitivity to vitamins A or E, or any component of the formulation, hypervitaminosis A.
Precautions	Vitamin E interacts with iron and other oxidants or any polyunsaturated fatty acids.
Danie internetiene	Vitamin E can increase serum bilirubin.
Drug interactions	Vitamin A may increase effects of anticoagulant and antiplatelet agents.
	Iron - Lowers bioavailability of Vitamin E.
Adverse reactions	Vitamin E may increase the effects of vitamin K antagonists and antiplatelet agents.  Hypervitaminosis A: Irritability, vomiting, bulging fontanelle.
Auverse reactions	Vitamin E: Sepsis, necrotising enterocolitis
Compatibility	Not applicable
Incompatibility	Not applicable  Not applicable
Stability	Trot applicable
Storage	Protect from light (all forms). Store below 25°C (room temperature)
Excipients	Bio-Logical Vitamin A & E oral solution contains sodium benzoate. Avoid exposure to sodium benzoate of
LACIPICITES	>99 mg/kg/day in neonates.
Special comments	
Evidence	See individual Vitamin A and Vitamin E monographs for evidence summaries.
LAIGELICE	See maistand vicamin A and vicamin E monographs for evidence summaties.

**ANMF consensus group** JHCH\_NICU\_19.168

Vitamin A and E solution

Page 1 of 2

# Vitamin A and E solution

#### **Newborn use only**

Practice points	
References	1. https://dietarysupplementdatabase.usda.nih.gov/Conversions.php. Accessed on 17 November 2021.
	2. Yang CH, Perumpail BJ, Yoo ER, Ahmed A, Kerner Jr. JA. Nutritional Needs and Support for Children
	with Chronic Liver Disease. Nutrients. 2017;9(10):1127.
	3. Hittner HM, Godio LB, Rudolph AJ, Adams JM, Garcia-Prats JA, Friedman Z, Kautz JA, Monaco WA.
	Retrolental fibroplasia: efficacy of vitamin E in a double-blind clinical study of preterm infants. New
	England journal of medicine. 1981 Dec 3;305(23):1365-71.

VERSION/NUMBER	DATE
Original 1.0	21/02/2022
REVIEW	21/02/2027

#### **Authors Contribution**

Original author/s	Michelle Jenkins, Renee Dimond
Evidence Review	Srinivas Bolisetty, Nilkant Phad, Karel Allegaert
Expert review	
Nursing Review	Priya Govindaswamy, Kirsty Minter, Eszter Jozsa, Sarah Neale
Pharmacy Review	Michelle Jenkins, Renee Dimond
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, John Sinn, Mohammad Irfan Azeem, Simarjit Kaur, Joanne
	Malloy, Carmen Burman, Helen Huynh, Hannah Bell
Final editing and review	Thao Tran
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty